Why invest in Atlas

Atlas Molecular Pharma´s business model is to exploit its innovative, cutting-edge and proprietary platform technology approach, which combined with the expertise of its high calibre and experienced team will deliver candidate drugs for patients suffering from devastating Rare and Ultra-Rare Diseases.

Our de-risked strategy will create value by delivering candidate drugs for multiple diseases suitable for pre-clinical licensing to larger Biotech and Pharma partners, positioning Atlas Molecular Pharma as a “Partner of Choice”.

Additional upside will be created by continuing to build a proprietary chemical resource/”drug discovery engine” suitable for forming potential collaborations/alliances with Biotech and Pharma partners.

Investors

Grants

[NEURO-COOP]
El proyecto EFA031/01 NEURO-COOP ha sido cofinanciado al 65% por la Unión Europea a través del Programa InterregVI-A España-Francia-Andorra (POCTEFA 2021-2027). El objetivo del POCTEFA es reforzar la integración económica y social de la zona fronteriza España-Francia-Andorra.

Presupuesto total: 1.824.070,45 euros. Subvención FEDER: 1.185.645,78 euros